From: Factors influencing adherence in Hepatitis-C infected patients: a systematic review
Study | Study type | Number of patients | Observation period | Inclusion criteria | Setting/country | Adherence measurement | Adherence operationalization | Adherence rate of patients |
---|---|---|---|---|---|---|---|---|
Giannelli 2012 [21] | Cohort study | 342 | 48 week | Transplantation for hepatitis-C virus-related liver disease | Liver transplantation centre/Italy | NR | Patients taking ≥80% of doses (ribavirin and interferon) | 0.38 |
Transplanted for at least 6 months | ||||||||
Positive test for anti-hepatitis-C virus and hepatitis-C virus RNA | ||||||||
Liver biopsy demonstrating a recurrence of chronic hepatitis-C | ||||||||
Treated with ribavirin plus peg-interferon interferon | ||||||||
No coexistent hepatitis-B | ||||||||
No cirrhosis | ||||||||
Lo Re [4] | Cohort study | 5706 | 90 days | US veterans | Veterans affairs medical facilities/USA | Pill count | Doses taken (ribavirin) | 0.86 |
Hepatitis-C virus infected | ||||||||
Genotype 1, 2, 3, or 4 | ||||||||
At least one prescription each for peg-interferon and ribavirin | ||||||||
Viral load prior to hepatitis-C virus therapy | ||||||||
Viral load after treatment initiation | ||||||||
Not HIV-infected | ||||||||
Marcellin 2011 [8] | Cohort study | 1510 | 6 month follow-up after end of treatment | Chronic hepatitis-C | University hospitals, non-University hospitals and private practice offices, hospitals/France | Self-report (doses taken) | Patients taking 100% of doses (peg-interferon alpha-2b and ribavirin) | 0.38 |
≥18 years | ||||||||
Initiating therapy | ||||||||
Therapy with peg-interferon alpha-2b and ribavirin | ||||||||
Martín-Santos 2008 [22] | Cohort study | 146 | 4-24 weeks | Chronic Hepatitis-C | Hospitals/Spain | NR | Patients taking ≥80% of doses (ribavirin) | 0.89 |
Therapy with peg-interferon alpha-2a and ribavirin | ||||||||
Substance abuse abstinence ≥ 6 months | ||||||||
No cognitive or language difficulties | ||||||||
No other liver diseases | ||||||||
No co-infection with hepatitis-B or HIV | ||||||||
No hepatocellular carcinoma | ||||||||
No autoimmune disorders | ||||||||
Neutrophil count f >1.5 × 109⁄l | ||||||||
Platelet count of >75 × 109⁄l | ||||||||
No psychiatric disorders other than affective disorders | ||||||||
Rodis [23] | Cohort study | 12 | 3 month | NR | Interdisciplinary HCV education and monitoring service/USA | Self-report (Morisky scale, Brief medication questionnaire) | Doses taken (interferon and ribavirin) | 1.00 |
Sola [24] | Cohort study | 157 | 72 weeks | Chronic Hepatitis-C and hepatitis-C virus RNA positive in plasma | Hospitals/Spain | Self-report via daily questionnaire (ribavirin and interferon) Pill counts (ribavirin) | Patients taking ≥80% of doses (ribavirin and interferon) | 0.76 |
≥18 years | ||||||||
Elevated alanin-aminotransferase levels | ||||||||
Findings on liver biopsy consistent with presence of chronic hepatitis-C , and compensated liver disease | ||||||||
CD4 cell count >200 × 106/mm3 regardless of plasma HIV RNA level or CD4 cell count <200 × 106/mm3 wiimes;th undetectable HIV RNA level | ||||||||
Neutrophil count ≥1500/mm3; platelet count ≥70,000/mm3; hemoglobin level ≥11 g/dl for women, or ≥12 g/dl for men | ||||||||
No previous treatment with interferon or ribavirin | ||||||||
No hepatitis-A or –B co-infection | ||||||||
No liver disease | ||||||||
No decompensated cirrhosis | ||||||||
No pregnancy | ||||||||
No active drug or alcohol consumption within the last 6 months | ||||||||
Potential contraindications to interferon or ribavirin | ||||||||
Sylvestre [25] | Cohort study | 71 | 48 weeks | Hepatitis-C | Clinic/USA | Self-report by monthly questionnaire Pill count | Patients taking >80% of doses (interferon alpha -2b and ribavirin) | 0.68 |
≥18 years | ||||||||
Maintained on methadone for 3 months | ||||||||
At least 75% attendance at our weekly clinics for a period of at least 2 months | ||||||||
No other liver disease | ||||||||
No untreated depression | ||||||||
Tanioka [26] | Cohort study | 363 | 8 months | Hepatitis-C | Hospitals/Japan | NR | Patients taking >80% of doses (interferon alpha -2b and ribavirin) | 0.52 |
≥18 years | ||||||||
Aminotransferase above the upper normal limit in the 6 months before entry in to the study | ||||||||
Compensated liver function with normal levels of serum albumin, prothrombin time and serum bilirubin | ||||||||
No chronic liver diseases | ||||||||
No injected drugs or abused alcohol within the previous 6 months | ||||||||
No poorly controlled psychiatric illness | ||||||||
Not HIV positive | ||||||||
No cirrhosis | ||||||||
Wagner [27] | Cross-sectional study | 72 | NA | Hepatitis-C virus | Veterans administration | Self-report (VAS) | Patients taking 100% of doses (peg-interferon and ribavirin) | 0.94 |
HIV | ||||||||
Interferon based hepatitis-C virus treatment | Medical center/USA |